FDA warns Evolus over misleading Instagram promotion of Jeuveau
On October 2, 2026 the U.S. Food and Drug Administration notified Evolus that an Instagram post for its injectable Jeuveau was false or misleading. The agency gave the company 15 working days to submit a corrective‑action plan. Following the warning, Evolus shares fell sharply, dropping more than 6.5% and trading around $7.23. Jeuveau generates over 90% of Evolus’ $316.5 million trailing‑twelve‑month revenue.
Why it matters
The FDA warning triggered an immediate sell‑off, with the stock down 6.5% and priced at $7.23, reflecting heightened regulatory risk for the company’s core product. Because Jeuveau supplies the majority of Evolus’ revenue, any further enforcement could materially affect future sales.
Key facts
- 1The FDA contacted Evolus on October 02, 2026 about a misleading Instagram post for Jeuveau. gurufocus.com
- 2Evolus shares fell more than 6.5% on Friday after the FDA announcement. stocktwits.com
- 3Shares were down 5.92% at $7.23 at the time of reporting. benzinga.com
- 4Jeuveau accounts for over 90% of Evolus’ revenue, which totaled $316.5 million over the trailing twelve months. gurufocus.com
- 5Evolus’ current price‑to‑sales ratio is 1.49. gurufocus.com
- 6Insiders have sold shares valued at $1.8 million in the past 12 months. gurufocus.com
Summary written by AlphAI from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.